Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

SC Agrotech Q2 Profit Jumps 48-Fold To ₹10.21 Crore, Revenue Surges 802% To ₹45.26 Crore

Mumbai: BSE-listed SC Agrotech Limited has reported a sharp rise in revenue and profitability for the quarter ended September 30, 2026. The agricultural trading company's net profit jumped nearly 48-fold, while revenue surged 802 percent year-on-year. The company is also exploring a digital agriculture platform, AgriBridge, as part of its proposed long-term expansion strategy. Profit Surge…

SC Agrotech Q2 Profit Jumps 48-Fold To ₹10.21 Crore, Revenue Surges 802% To ₹45.26 Crore

Mumbai-based SC Agrotech Limited announced a dramatic increase in profits and revenue for the second quarter of fiscal year 2027, ending September 30. The agricultural trading firm's net profit jumped nearly 48 times higher, reaching ₹10.21 crore, compared to just ₹21.21 lakh in the same period last year. Revenue from operations surged 802 percent, reaching ₹45.26 crore, up from ₹5.02 crore.

The company is in the early stages of developing a digital agriculture platform called AgriBridge, which aims to streamline transactions between farmers and institutional buyers. Despite strong earnings, operating cash flow remained negative, with trade receivables rising to ₹122.60 crore. Investors should watch for sustained profitability, improved cash collections, and successful execution of AgriBridge as key factors moving forward.

Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at freepressjournal.in →

More in Finance & Markets

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.

  • Axsome Therapeutics focuses on CNS disorders with Auvelity, Sunosi, and Symbravo pipeline drugs.
  • Moderna's revenue declines due to COVID-19 vaccine demand drop and competition.
  • Axsome shows positive revenue trends, while Moderna experiences volatility.

More from Wednesday 28 October →